Stock 4516 NIPPON SHINYAKU CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
3,207 JPY +1.20% Intraday chart for Nippon Shinyaku Co., Ltd. +1.46% -35.81%
04-10 Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy MT
03-18 Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Nippon Shinyaku : Japan’s PMDA approves Antineoplastic Agent "Jaypirca® 50 mg and 100 mg tablets" for Patients with Relapsed or Refractory MCL Who are Resistant or Intolerant to Other BTK Inhibitors
PU
Nippon Shinyaku : Notice of The 161st Annual General Meeting of Shareholder
PU
Nippon Shinyaku : The 7th Five Year Medium Term Management Plan "For Global Growth Beyond the Cliff”
PU
Nippon Shinyaku : Viltolarsen (NS 065/NCNP 01) for the treatment of Duchenne Muscular Dystrophy Preliminary Results of the Analysis of the Phase III Trial (RACER53 Study)
PU
Nippon Shinyaku : Notice Regarding Introduction of a Restricted Stock Compensation Plan
PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (Script+Q&A(Summary))P
PU
Nippon Shinyaku : Launch of VyxeosⓇ Combination for I.V. Injection for the Treatment of High-risk AML in Japan
PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (Script)P
PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR MeetingP
PU
Nippon Shinyaku : Outline of Consolidated Financial Results for the Year Ended March 31, 2024
PU
Interim report January-March 2024
AQ
Nippon Shinyaku : Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW
PU
Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy
MT
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
AQ
Nippon Shinyaku : Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System
PU
Final dividend
FA
Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan
PU
Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan
PU
Nippon Shinyaku : Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan
PU
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4516 Stock
  4. News Nippon Shinyaku Co., Ltd.